Objective: To determine the effects of “prolonged” antiplatelet therapy (that is, given for one month or more) on “vascular events”(non-fatal myocardial infarctions, non-fatal strokes, or …
The role of aspirin and other platelet-active drugs in the treatment and prevention of atherothrombosis has been reviewed recently by the Sixth American College of Chest …
A Trialists' Collaboration - Bmj, 1994 - ncbi.nlm.nih.gov
OBJECTIVE--To determine the efficacy of antiplatelet therapy in maintaining vascular patency in various categories of patients. DESIGN--Overviews of 46 randomised trials of …
OBJECTIVE To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile. DESIGN Meta …
C Patrono - European heart journal, 2013 - academic.oup.com
Low-dose aspirin has been shown to be effective in preventing about one-fifth of atherothrombotic vascular complications (non-fatal myocardial infarction, non-fatal stroke, or …
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known …
Objective: To determine which groups of patients may derive particular benefit or experience harm from the use of low dose aspirin for the primary prevention of coronary heart disease …
CH Hennekens - American Journal of Managed Care, 2002 - ajmc.s3.amazonaws.com
Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial …
C Baigent, L Blackwell, R Collins, J Emberson… - …, 2009 - researchonline.lshtm.ac.uk
BACKGROUND: Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in …